Restless legs syndrome clinical trials

Explore recruiting restless legs syndrome clinical trials.

Recruiting restless legs syndrome studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Restless legs syndrome trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

Intravenous iron in the management of drug-resistant restless legs syndrome: a randomized controlled delayed-start trial. IRON-RLS

France

Therapeutic exploratory (Phase II) EU CTIS Study details

A Proof of Concept, Multicentre, Phase 2, Double- Blind, Randomized, Placebo-Controlled Study on the Efficacy, Safety and Tolerability of d-Methadone in Moderate to Very Severe Restless Legs Syndrome with Periodic Limb Movements: the Glu-REST Study

Italy

Therapeutic exploratory (Phase II) EU CTIS Study details

Prospective analysis of the therapeutic efficacy of iron isomaltoside in combination with or without dopaminergic therapy in patients with restless legs syndrome

Austria

Therapeutic confirmatory (Phase III) EU CTIS Study details

An open label, randomized, crossover, two-period, two-sequence, multiple dose study to assess the relative bioavailability of Rotigotine 4.5 mg (2 mg/24 hrs) transdermal patch (Test Product) compared to Neupro® 2 mg/24 h Transdermal Patch (Reference product) in 48 healthy adult volunteers under fasting conditions.

Czechia

Human Pharmacology (Phase I)- Bioequivalence Study EU CTIS Study details

An open label, randomized, crossover, two-period, two-sequence, single dose study to assess the relative bioavailability of Rotigotine 4.5 mg (2 mg/24 hrs) transdermal patch (Test Product) compared to Neupro® 2 mg/24 h Transdermal Patch (Reference product) in 48 healthy adult volunteers under fasting conditions.

Czechia

Human Pharmacology (Phase I)- Bioequivalence Study EU CTIS Study details

Restless legs syndrome trials by city

Restless legs syndrome in Toronto Restless legs syndrome in Vancouver Restless legs syndrome in Montreal Restless legs syndrome in Calgary Restless legs syndrome in Edmonton Restless legs syndrome in Ottawa Restless legs syndrome in Winnipeg Restless legs syndrome in Quebec City Restless legs syndrome in Hamilton Restless legs syndrome in Kitchener Restless legs syndrome in London Restless legs syndrome in Halifax Restless legs syndrome in New York Restless legs syndrome in Los Angeles Restless legs syndrome in Chicago Restless legs syndrome in Houston

Other conditions

Chronic kidney disease Diabetic kidney disease IgA nephropathy Polycystic kidney disease Migraine Alzheimer's disease Parkinson's disease Multiple sclerosis Epilepsy ALS Huntington's disease Peripheral neuropathy Essential tremor Dementia Depression Anxiety Bipolar disorder Schizophrenia PTSD OCD ADHD Insomnia Postpartum depression Alcohol use disorder